SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Feasibility randomised controlled trial of online group Acceptance and Commitment Therapy for Functional Cognitive Disorder (ACT4FCD).

Poole, N; Cope, S; Vanzan, S; Duffus, A; Mantovani, N; Smith, J; Barrett, BM; Tokley, M; Scicluna, M; Beardmore, S; et al. Poole, N; Cope, S; Vanzan, S; Duffus, A; Mantovani, N; Smith, J; Barrett, BM; Tokley, M; Scicluna, M; Beardmore, S; Turner, K; Edwards, M; Howard, R (2023) Feasibility randomised controlled trial of online group Acceptance and Commitment Therapy for Functional Cognitive Disorder (ACT4FCD). BMJ Open, 13 (5). e072366. ISSN 2044-6055 https://doi.org/10.1136/bmjopen-2023-072366
SGUL Authors: Mantovani, Nadia

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (13MB) | Preview

Abstract

INTRODUCTION: Functional cognitive disorder (FCD) is seen increasingly in clinics commissioned to assess cognitive disorders. Patients report frequent cognitive, especially memory, failures. The diagnosis can be made clinically, and unnecessary investigations avoided. While there is some evidence that psychological treatments can be helpful, they are not routinely available. Therefore, we have developed a brief psychological intervention using the principles of acceptance and commitment therapy (ACT) that can be delivered in groups and online. We are conducting a feasibility study to assess whether the intervention can be delivered within a randomised controlled trial. We aim to study the feasibility of recruitment, willingness to be randomised to intervention or control condition, adherence to the intervention, completion of outcome measures and acceptability of treatment. METHODS AND ANALYSIS: We aim to recruit 48 participants randomised 50:50 to either the ACT intervention and treatment as usual (TAU), or TAU alone. ACT will be provided to participants in the treatment arm following completion of baseline outcome measures. Completion of these outcome measures will be repeated at 8, 16 and 26 weeks. The measures will assess several domains including psychological flexibility, subjective cognitive symptoms, mood and anxiety, health-related quality of life and functioning, healthcare utilisation, and satisfaction with care and participant-rated improvement. Fifteen participants will be selected for in-depth qualitative interviews about their experiences of living with FCD and of the ACT intervention. ETHICS AND DISSEMINATION: The study received a favourable opinion from the South East Scotland Research Ethics Committee 02 on 30 September 2022 (REC reference: 22/SS/0059). HRA approval was received on 1 November 2022 (IRAS 313730). The results will be published in full in an open-access journal. TRIAL REGISTRATION NUMBER: ISRCTN12939037.

Item Type: Article
Additional Information: © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Keywords: Delirium & cognitive disorders, NEUROLOGY, PSYCHIATRY, Humans, Acceptance and Commitment Therapy, Quality of Life, Feasibility Studies, Cognitive Dysfunction, Outcome Assessment, Health Care, Humans, Feasibility Studies, Quality of Life, Acceptance and Commitment Therapy, Cognitive Dysfunction, Outcome Assessment, Health Care, PSYCHIATRY, NEUROLOGY, Delirium & cognitive disorders, 1103 Clinical Sciences, 1117 Public Health and Health Services, 1199 Other Medical and Health Sciences
SGUL Research Institute / Research Centre: Academic Structure > Population Health Research Institute (INPH)
Journal or Publication Title: BMJ Open
ISSN: 2044-6055
Language: eng
Dates:
DateEvent
11 May 2023Published
12 April 2023Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
NIHR202743Research for Patient Benefit Programmehttp://dx.doi.org/10.13039/501100009128
PubMed ID: 37169496
Web of Science ID: WOS:001001500800025
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/115548
Publisher's version: https://doi.org/10.1136/bmjopen-2023-072366

Actions (login required)

Edit Item Edit Item